Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Patent: 7,217,519

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,217,519
Title:Histoplasma capsulatum chitin synthase sequences and their use for detection of Histoplasma capsulatum and histoplasmosis
Abstract: The present invention describes Histoplasmosis capsulatum chitin synthase nucleic acid and protein sequences as reagents for the detection of H. capsulatum infection. Specifically, the invention describes intron sequences from the H. capsulatum chitin synthase gene which can be used for hybridization-based and PCR-based detection of H. capsulatum infection. In another embodiment, assays for H. capsulatum chitin synthase 2 polypeptide and/or mRNA used as a diagnostic test for H. capsulatum infection and/or histoplasmosis. Also described is the differentiation of H. capsulatum from Blastomyces dermititidis based on detection of intron 1 sequences specific to H. capsulatum chitin synthase 2. The present invention also comprises the production of H. capsulatum strains lacking functional chitin synthase 2 as a means to produce H. capsulatum having reduced pathogenicity.
Inventor(s): Johnson; Clayton H. (Little Rock, AR), McEwen; Joan E. (Little Rock, AR)
Assignee: The Board of Trustees of the University of Arkansas (Little Rock, AR)
Application Number:10/718,955
Patent Claims:see list of patent claims

Details for Patent 7,217,519

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2022-11-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2022-11-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.